April 2015 | HCC Monitor

Evolution of Treatment for HCC: Sorafenib and Beyond

May 08, 2015

Clinical Articles

The small molecule multikinase inhibitor sorafenib remains the only molecularly targeted therapy approved by the FDA for the treatment of hepatocellular carcinoma, with ongoing clinical trials diligently testing the potential for novel targeted agents or combination therapies to further improve patient outcomes in this setting.

New Model Improves Liver Function Assessment in HCC

May 16, 2015

Clinical Articles

A novel, evidence-based model for staging liver function in the setting of hepatocellular carcinoma may offer improved guidance in the selection of appropriate, patient-specific therapeutic strategies.